DRUG REVIEW : OKSITOSIN DAN MISOPROSTOL PADA POSTPARTUM HEMORRHAGE (PPH)

Postpartum Hemorrhage (PPH) is an extremely important cause of maternal mortality and
morbidity throughout the world. All guidelines recommend intramuscular oxytocin as the firstline
uterotonic treatment for all women who giving birth during the third trimester of labor. This
treatment is for the prevention of PPH due to its efficacy and safety, whereas misoprostol is used
as an alternative in conditions where oxytocin is not available or in areas where the patient does
not have access to skilled care. The purpose of this study was to compare the use of oxytocin
and misoprostol in PPH patients. This study is a narrative review conducted by literature
searches in several scientific journals through Google Scholar, Pubmed and Science Direct.
From the search results, obtained as many as 5855 journals and selected 40 journals that meet
the inclusion criteria. The inclusion criteria are to meet the rules of introduction, method results
and discussion and have been published for the last 10 years. Journals that could not be
accessed completely were excluded and 23 journals were obtained. The results of the review
showed that oxytocin prophylaxis reduced blood loss and the incidence of PPH without adverse
outcomes. The use of oxytocin with Uniject also provides an advantage in cost savings.
However, the use of oxytocin should be given by a professional. Misoprostol is an effective
alternative for the treatment of primary PPH. However, the use of misoprostol is associated with
some side effects, so it is given when the availability of oxytocin is limited. Thus, it can be
concluded that the